Comprehensive Diagnostic & Therapeutic Reference Profile
Also known as: Psoriasis vulgaris, Plaque psoriasis, PsA (Psoriatic Arthritis)
Psoriasis is a chronic, immune-mediated, systemic inflammatory disease primarily characterized by the hyperproliferation of keratinocytes. It manifests as well-circumscribed, erythematous plaques covered with silvery scales. While predominantly cutaneous, it is recognized as a systemic condition associated with comorbidities including cardiovascular disease and metabolic syndrome.
Psoriasis is polygenic, with a strong association with the HLA-Cw6 allele. Environmental triggers include infections (e.g., Streptococcal), physical trauma (Koebner phenomenon), stress, smoking, alcohol, and certain medications like beta-blockers or lithium.
The disease involves a complex interplay between the innate and adaptive immune systems. T-helper 17 (Th17) cells secrete IL-17 and IL-23, signaling keratinocytes to undergo rapid, aberrant turnover (3–5 days vs. the normal 28–30 days), resulting in parakeratosis and acanthosis.
Psoriasis affects 2–3% of the global population. It typically presents in two peaks: late adolescence (15–20) and mid-adulthood (55–60). There is no significant gender bias.
Genetic predisposition, obesity, metabolic syndrome, psychological stress, tobacco use, and chronic infections.
A. Early Symptoms
A. Clinical Assessment: History and visual inspection.
B. Laboratory Testing: Usually for ruling out mimics or monitoring biologics.
C. Imaging Studies: X-rays for psoriatic arthritis.
D. Functional Tests: PASI score for severity.
E. Biopsy Findings: Parakeratosis, acanthosis, and Munro’s microabscesses.
F. Genetic Testing: Generally not required for diagnosis.
G. Differential Diagnosis: Eczema, seborrheic dermatitis, tinea.
Complete Blood Count (CBC)
Type: Blood Test
Purpose: Evaluate systemic inflammation
Expected Findings: Mild leukocytosis
Interpretation: Indicates active inflammatory burden
X-ray (Joints)
Purpose: Screen for PsA
Typical Findings: Marginal erosions and "pencil-in-cup" deformities.
Psoriatic arthritis, cardiovascular disease, depression, metabolic syndrome, and ocular inflammation (uveitis).
A. Lifestyle Modifications: Weight loss, smoking cessation, stress management.
B. Preventive Measures: Avoidance of triggers (Koebner trauma).
C. Medical Treatment: Topical corticosteroids, vitamin D analogues, phototherapy (UVB), Methotrexate, TNF-inhibitors (Adalimumab).
D. Surgical Treatment: Rarely, joint reconstruction for severe arthritis.
E. Interventional Procedures: Excimer laser.
F. Rehabilitation: Physical therapy for arthritis.
G. Emergency Management: Hospitalization for fluid management in erythrodermic psoriasis.
Chronic condition; periods of remission and exacerbation. Not curable but highly manageable.
Screening for comorbidities; early therapeutic intervention to limit disease activity.
The following homeopathic remedies have been historically indicated for symptoms associated with Psoriasis. Selection should be based on individualized symptom totality and constitutional assessment.
This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.
Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Psoriasis.
Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, identify reference range variances, and generate a plain-English explanation of your disease risks.
Browse our full library of 200+ medical and pathology calculators.
📊 Browse All CalculatorsSpeak with our specialists for a customized treatment protocol for this condition.
📅 Request ConsultationThis clinical reference is for educational purposes only. It is not a substitute for professional medical diagnosis or treatment. Always consult a licensed healthcare practitioner.